BioLargo (BLGO) 15th Annual LD Micro Invitational 2025 summary

Business model and innovation strategy

• Focus on innovation-driven, purpose-led business with a refined model for impact and profitability.

• Operates with a capital-conserving approach: invent, prove, and partner to maximize value.

• Four operating units supported by a world-class engineering team, with 45 employees including 12 PhDs and 27 engineers.

• Leverages external grants and incentives, especially from Canada, to support R&D.

• Business model centers on discovery, validation, channel development, and strategic partnerships for distribution.

Key product lines and market opportunities

• Portfolio includes odor and VOC control, infection control and wound care, water and PFAS treatment, and advanced battery technology.

• PFAS remediation targets a $17 trillion global issue, with solutions for water, cosmetics, food, and pharmaceuticals.

• POOPH, a pet odor product, generated $5.9 million in free cash flow last year and is valued at $250–$300 million, with a 20% ownership stake.

• Pad business secured a major global customer after a $3.7 million investment in equipment and supply chain readiness.

• Infection control product, co-branded with a partner holding 90% market share, expected to generate $40–$50 million in first-year revenue and scale to hundreds of millions.

Financial performance and asset value

• Operating model generates revenue from manufacturing, royalties, and carried interest in brands.

• Assets are structured for long-term value growth, with unseen value not fully reflected in current stock price.

• Infection control product required $20 million and 14 years of development, targeting a $500 million market cap within 18 months and over $1 billion in value.

• Manufacturing partnerships and capital investments are key to scaling and securing intellectual property.